Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Ralph Corey

Showing results (41-50 of 157) with videos related to

Pageof 16
Sort By:
Diagnostic Microbiology and Infectious Disease|January 1, 2017
Assessment of telavancin minimal inhibitory concentrations by revised broth microdilution method in phase 3 complicated skin and skin-structure infection clinical trial isolatesJennifer I Smart, G Ralph Corey, Martin E Stryjewski, et al.
Antimicrobial Agents and Chemotherapy|January 24, 2018
Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO StudiesG Ralph Corey, Jeffery Loutit, Greg Moeck, et al.
The Journal of Antimicrobial Chemotherapy|December 1, 2010
CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infectionsMark H Wilcox, G Ralph Corey, George H Talbot, et al.
The Journal of Antimicrobial Chemotherapy|December 1, 2010
CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infectionsG Ralph Corey, Mark H Wilcox, George H Talbot, et al.
Diagnostic Microbiology and Infectious Disease|January 8, 2018
Surveillance of iclaprim activity: In vitro susceptibility of gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin American and EuropeDavid B Huang, Thomas M File, Matthew Dryden, et al.
The Lancet. Infectious Diseases|June 10, 2014
Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trialGregory J Moran, Edward Fang, G Ralph Corey, et al.
Journal of Medical Microbiology|September 16, 2003
Fatal outcome of bacteraemic patients caused by infection with staphylokinase-deficient Staphylococcus aureus strainsTao Jin, Maria Bokarewa, Lauren McIntyre, et al.
Circulation|September 15, 2005
Clinical predictors of major infections after cardiac surgeryVance G Fowler, Sean M O'Brien, Lawrence H Muhlbaier, et al.
Clinical Cardiology|August 4, 2005
The significance of elevated troponin T in patients with nondialysis-dependent renal insufficiency: a validation with coronary angiographyJohn F Heitner, Jeptha P Curtis, Salman A Haq, et al.
Antimicrobial Agents and Chemotherapy|November 26, 2014
Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infectionsAndrew F Shorr, Thomas P Lodise, G Ralph Corey, et al.
Pageof 16

Showing results (41-50 of 157) with videos related to

Sort By:
Pageof 16
Diagnostic Microbiology and Infectious Disease|January 1, 2017
Assessment of telavancin minimal inhibitory concentrations by revised broth microdilution method in phase 3 complicated skin and skin-structure infection clinical trial isolatesJennifer I Smart, G Ralph Corey, Martin E Stryjewski, et al.
Antimicrobial Agents and Chemotherapy|January 24, 2018
Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO StudiesG Ralph Corey, Jeffery Loutit, Greg Moeck, et al.
The Journal of Antimicrobial Chemotherapy|December 1, 2010
CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infectionsMark H Wilcox, G Ralph Corey, George H Talbot, et al.
The Journal of Antimicrobial Chemotherapy|December 1, 2010
CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infectionsG Ralph Corey, Mark H Wilcox, George H Talbot, et al.
Diagnostic Microbiology and Infectious Disease|January 8, 2018
Surveillance of iclaprim activity: In vitro susceptibility of gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin American and EuropeDavid B Huang, Thomas M File, Matthew Dryden, et al.
The Lancet. Infectious Diseases|June 10, 2014
Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trialGregory J Moran, Edward Fang, G Ralph Corey, et al.
Journal of Medical Microbiology|September 16, 2003
Fatal outcome of bacteraemic patients caused by infection with staphylokinase-deficient Staphylococcus aureus strainsTao Jin, Maria Bokarewa, Lauren McIntyre, et al.
Circulation|September 15, 2005
Clinical predictors of major infections after cardiac surgeryVance G Fowler, Sean M O'Brien, Lawrence H Muhlbaier, et al.
Clinical Cardiology|August 4, 2005
The significance of elevated troponin T in patients with nondialysis-dependent renal insufficiency: a validation with coronary angiographyJohn F Heitner, Jeptha P Curtis, Salman A Haq, et al.
Antimicrobial Agents and Chemotherapy|November 26, 2014
Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infectionsAndrew F Shorr, Thomas P Lodise, G Ralph Corey, et al.
Pageof 16